KAI Pharmaceuticals
Executives
9Board of Directors
1KAI Pharmaceuticals Management Team
9 Team Members
KAI Pharmaceuticals has 9 executives. KAI Pharmaceuticals's founder is Leon Chen. KAI Pharmaceuticals's is .
Name | Work History | Title | Status |
|---|---|---|---|
Leon Chen | OrbiMed Advisors, Skyline Ventures, and Venrock | Founder | Current |
Name | Leon Chen | ||||
|---|---|---|---|---|---|
Work History | OrbiMed Advisors, Skyline Ventures, and Venrock | ||||
Title | Founder | ||||
Status | Current |
This profile has not been claimed.
Highlight your management team’s expertise.
KAI Pharmaceuticals Board of Director
1 Board of directors
KAI Pharmaceuticals has 1 board of directors, including Chris Ehrlich.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Chris Ehrlich | Chris Ehrlich has been part of InterWest's life sciences team since 2000, focusing on investments in novel therapeutic approaches. He currently serves on the boards of two publicly owned companies: BioMimetic Therapeutics (BMTI) and Transcept Pharmaceuticals (TSPT). He also serves on the boards of several private companies, including: Carbylan BioSurgery, Follica, KAI Pharmaceuticals, QuatRx Pharmaceuticals, Satori Pharmaceuticals, Solace Pharmaceuticals, and Xenon Pharmaceuticals. Ehrlich played a role in InterWest's investment in Applied Genetic Technologies Corporation, and was involved with founding AlgoRx Pharmaceuticals, which merged with Anesiva (ANSV). Prior to joining InterWest, Ehrlich was director, licensing and business development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. In this position, he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Ehrlich worked in business development at Genentech, in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. Ehrlich received his B.A. from Dartmouth College, cum laude, and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University where he serves as an instructor and advisor to the Biotech program. A Word from Chris "Over the past several years, I've had the opportunity to help a variety of new companies successfully commercialize their technologies. While providing strategic advice to medical technology startups, launching new entrepreneurial ventures in post-Soviet Russia, and in-licensing new biotechnologies for major biotech and pharmaceutical companies, I've learned a lot about what's required to transform great concepts into viable businesses. As a member of the Life Sciences team at InterWest, I have the opportunity to work alongside the scientists, technologists and physicians who are creating the future of healthcare &mdash | KAI Pharmaceuticals |
Name | Chris Ehrlich |
|---|---|
Firm | |
Work History | Chris Ehrlich has been part of InterWest's life sciences team since 2000, focusing on investments in novel therapeutic approaches. He currently serves on the boards of two publicly owned companies: BioMimetic Therapeutics (BMTI) and Transcept Pharmaceuticals (TSPT). He also serves on the boards of several private companies, including: Carbylan BioSurgery, Follica, KAI Pharmaceuticals, QuatRx Pharmaceuticals, Satori Pharmaceuticals, Solace Pharmaceuticals, and Xenon Pharmaceuticals. Ehrlich played a role in InterWest's investment in Applied Genetic Technologies Corporation, and was involved with founding AlgoRx Pharmaceuticals, which merged with Anesiva (ANSV). Prior to joining InterWest, Ehrlich was director, licensing and business development at Purdue Pharma, a private pharmaceutical firm based in Stamford, CT. In this position, he was responsible for developing a biologic oncology franchise, including in-licensing key intellectual properties, establishing and managing collaborations with biotechnology companies and participating in the commercial operations of Purdue BioPharma, a biotechnology company located in Princeton, NJ. Prior to joining Purdue, Ehrlich worked in business development at Genentech, in venture capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at LEK Consulting. Ehrlich received his B.A. from Dartmouth College, cum laude, and an M.B.A. from the J.L. Kellogg Graduate School of Management at Northwestern University where he serves as an instructor and advisor to the Biotech program. A Word from Chris "Over the past several years, I've had the opportunity to help a variety of new companies successfully commercialize their technologies. While providing strategic advice to medical technology startups, launching new entrepreneurial ventures in post-Soviet Russia, and in-licensing new biotechnologies for major biotech and pharmaceutical companies, I've learned a lot about what's required to transform great concepts into viable businesses. As a member of the Life Sciences team at InterWest, I have the opportunity to work alongside the scientists, technologists and physicians who are creating the future of healthcare &mdash |
Other Seats | KAI Pharmaceuticals |
Compare KAI Pharmaceuticals to Competitors
Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.
Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
Quark Pharmaceuticals is a development-stage pharmaceutical company discovering and developing RNA interference (RNAi)-based therapeutics.
Marillion Pharmaceuticals, Inc. - Marillion is developing clinical-stage drugs in oncology and oncology supportive care. 177Lu-AMBA is a targeted radiotherapeutic, with the low level radiation of lutetium that aims to utilize an receptor-based technology, and can serve as both a diagnostic and therapeutic agent. The targeting capability means that 177Lu-AMBA homes in on tumor cells and spares normal tissues. 177Lu-AMBA is being pursued initially to treat hormone-resistant prostate cancer, has been studied in a phase I trial in Europe. Marillion also is developing PilobucTM , buccal formulation of pilocarpine ,for the treatment of dry mouth, shown in clinical trials to effectively and conveniently deliver the drug with reduced side effects compared to other routes of administration.PilobucTM buccal formulation of pilocarpine has the potential to be a product in the xerostomia market. Marillion is preparing for phase II trials of the product candidate..
Radius Health is a biopharmaceutical company focused on developing new therapeutics to treat osteoporosis and other women's health conditions. It is committed to the development of therapeutics for the osteoporosis market. The company's lead product candidate, BA058-SC, is in effect to reduce the risk of complications associated with osteoporosis, such as fractures and has a transdermal patch, BA058-TD, being developed as a short wear-time delivery vehicle intended to improve patient compliance with convenience and ease of use, as well as a product in development to treat symptoms associated with menopause. The company was founded in 2003 and is based in Boston, Massachusetts.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.